157258 Results

Show all   Save search   Copy query
Sort   by:  
 Page size 
MetabolomicsThe cardiovascular risk of healthy individuals studied by NMR metabonomics of plasma samples
The identification and the present wide acceptance of cardiovascular risk factors such as age, sex, hypertension, hyperlipidemia, smoking, obesity, diabetes, and physical inactivity have led to dramatic reductions in cardiovascular morbidity and mortality. However, novel risk predictors present oppo...
2015-03-03 | MTBLS46 | MetaboLights
MetabolomicsProbabilistic networks of blood metabolites in healthy subjects as indicators of latent cardiovascular risk
The complex nature of the mechanisms behind cardiovascular diseases prevents the detection of latent early risk conditions. Network representations are ideally suited to investigate the complex interconnections between the individual components of a biological system underlying complex diseases. Her...
2015-01-01 | MTBLS147 | MetaboLights
MetabolomicsMulti-Omic Analysis and Platelet Function Distinguish Treatment Responses to Hydroxytyrosol in Cardiovascular Risk
Many polyphenols have been recognized for their antioxidant and health benefits. The present study attempted, for the first time, to determine the effects of daily oral intake of β-cyclodextrin-encapsulated hydroxytyrosol (HT) on plasma platelet reactivity and proteomic and metabolomic profiles of p...
2025-06-30 | MTBLS12336 | MetaboLights
MetabolomicsMetabolomic profiling of mouse heart in a model of Cardiovascular-Kidney-Metabolic syndrome

Cardiovascular-kidney-metabolic (CKM) syndrome is a complex systemic disorder. In this study, we developed a urea-activated nanoparticle (T-PAAD NP) for targeted delivery of Empagliflozin to the renal S1 segment. Untargeted GC-MS-based metabolomics was performed to characterize metabolic reprogra...

2026-03-21 | MTBLS13991 | MetaboLights
MetabolomicsMetabolomic profiling of mouse kidney in a model of Cardiovascular-Kidney-Metabolic syndrome

Cardiovascular-kidney-metabolic (CKM) syndrome is a complex systemic disorder. In this study, we developed a urea-activated nanoparticle (T-PAAD NP) for targeted delivery of Empagliflozin to the renal S1 segment. Untargeted GC-MS-based metabolomics was performed to characterize metabolic reprogra...

2026-03-21 | MTBLS13988 | MetaboLights
MetabolomicsAntidiabetic and cardiovascular beneficial effects of a liver-localized mitochondrial uncoupler
Inducing mitochondrial uncoupling (mUncoupling) is an attractive therapeutic strategy for treating metabolic diseases because it leads to calorie-wasting by reducing the efficiency of oxidative phosphorylation (OXPHOS) in mitochondria. Here we report a safe mUncoupler, OPC-163493, which has unique p...
2019-05-24 | MTBLS836 | MetaboLights
MetabolomicsSleep apnea and cardiovascular samples ceramide concentrations
Not available
ORGANISM(S): Homo sapiens 
ST000492 | MetabolomicsWorkbench
MetabolomicsSleep apnea and cardiovascular samples nueromodulators panel
Not available
ORGANISM(S): Homo sapiens 
ST000490 | MetabolomicsWorkbench
MetabolomicsSleep apnea and cardiovascular samples amino acid metabolites
Not available
ORGANISM(S): Homo sapiens 
ST000491 | MetabolomicsWorkbench
MetabolomicsCyclooxygenase-2, Asymmetric Dimethylarginine, and the Cardiovascular Hazard From Nonsteroidal Anti-Inflammatory Drugs (Murine kidney and plasma UPLC-MS/MS assay)

BACKGROUND: Large-scale, placebo-controlled trials established that nonsteroidal anti-inflammatory drugs confer a cardiovascular hazard: this has been attributed to depression of cardioprotective products of cyclooxygenase (COX)-2, especially prostacyclin. An alternative mechanis...

2019-08-22 | MTBLS680 | MetaboLights
Sort   by:  
 Page size